摘要
目的探讨肝动脉栓塞术(TAE)联合FOLFOX4方案持续动脉灌注化疗对肝细胞癌(HCC)伴门静脉癌栓(PVTT)患者的近期疗效。方法选择潮州市中心医院2017年6月至2020年6月收治的HCC伴PVTT患者70例,采用随机数字表法分为两组,每组各35例。试验组予以TAE+FOLOX4方案持续动脉灌注化疗,对照组予以肝动脉化疗栓塞术(TACE)治疗。比较两组患者疾病控制率、不良反应发生率及生物标志物。结果两组HCC疾病控制率比较,差异无统计学意义(P>0.05);试验组PVTT疾病控制率高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05);术后试验组胰岛素样生长因子Ⅱ(IGF-Ⅱ)、胰岛素样生长因子结合蛋白-2(IGBP-2)水平低于对照组,差异有统计学意义(P<0.05)。结论TAE联合FOLFOX4方案持续动脉灌注化疗对HCC伴PVTT患者效果显著,患者PVTT疾病控制率提高且肿瘤负荷降低,值得推广。
Objective To investigate the short-term efficacy of transcatheter arterial embolization(TAE)combined with FOLFOX4 regimen of continuous arterial infusion chemotherapy on hepatocellular carcinoma(HCC)patients with portal vein tumor thrombus(PVTT).Methods A total of 70 HCC patients with PVTT admitted to and treated in the Chaozhou Central Hospital from June 2017 to June 2020 were selected,and they were divided into the experimental group(n=35)and the control group(n=35)according to the random number table method.The experimental group was treated with TAE+FOLOX4 regimen of continuous arterial infusion chemotherapy,while the control group was treated with transcatheter arterial chemoembolization(TACE).The disease control rate,incidence of adverse reactions(ADRs)and biomarkers were compared between the two groups of patients.Results There was no statistically significant difference in HCC disease control rate between the two groups(P>0.05).The disease control rate of PVTT in the experimental group was higher than that in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of ADRs between the two groups(P>0.05).After operation,the levels of insulin-like growth factor-Ⅱ(IGF-Ⅱ)and insulin-like growth factor binding protein-2(IGBP-2)in the experimental group were lower than those in the control group,with statistically significant differences(P<0.05).Conclusion TAE+FOLOX4 regimen of continuous arterial infusion chemotherapy is remarkably effective on HCC patients with PVTT.It can improve the disease control rate for patients with PVTT and reduce the tumor load,which is worthy of promotion.
作者
柯映平
叶绍光
卢舜彬
KE Yingping;YE Shaoguang;LU Shunbin(Department of General Surgery,Chaozhou Central Hospital,Guangdong,Chaozhou 521000,China)
出处
《中国医药科学》
2022年第16期156-159,共4页
China Medicine And Pharmacy
基金
广东省潮州市卫生健康局科研项目(潮卫科研2020068号)。
关键词
肝动脉栓塞术
FOLOX4方案
持续动脉灌注化疗
肝细胞癌
门静脉癌栓
Transcatheter arterial embolization
FOLOX4 regimen
Continuous arterial infusion chemotherapy
Hepatocellular carcinoma
Portal vein tumor thrombus
